Table 3 The response on use of intra-pleural fibrinolytic and DNase for pleural infection according to the hospital setting with or without on-site thoracic surgery
| Â | Total number of survey participants (n=129) | |
|---|---|---|
Hospitals with on-site thoracic surgical unit (n=43) | Hospitals without on-site thoracic surgical unit (n=86) | |
Use of intra-pleural fibrinolytic and DNase for pleural infectionb | Yes: 22 | Yes: 24 |
No: 21 | No: 62 | |
| Â | Reasons of not using intra-pleural fibrinolytic and DNase for pleural infectiona | |
N=21 | N=62 | |
• Medications not readily available | 11 (52%) | 22 (35%) |
• More confidence in thoracic surgical approach | 1 (5%) | 3 (5%) |
• Concerns on side effects | 2 (10%) | 3 (5%) |
• Concerns on drug cost not covered by public funding | 7 (33%) | 13 (21%) |
• Not aware of this treatment | 4 (19%) | 21 (34%) |
• Others/not specified | 4 (19%) | 10 (16%) |